



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

ELI LILLY AND COMPANY

By Linda M. Dunbar Date October 20, 2004

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of
U.S. Patent No. 6,008,216

Applicants:	Chakrabarti et al.) Confirmation No.:
) 4078
Serial No.:	10/023,132)
) Group Art Unit:
Filing Date:	December 18, 2001) 1624
)
For:	PROCESS FOR PREPARING 2-METHYL- THIENO-BENZODIAZEPINE)
) Examiner:
) Brenda L. Coleman
Docket No.:	G-1265I)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, Applicants submit a copy of each of the documents listed on the attached Form PTO-1449 (modified) for consideration by the Examiner.

Applicants wish to bring to the attention of the Office that the validity of U.S. Patent No. 5,229,382 is currently being challenged in United States District Court, Southern District of Indiana, Docket No. IP01-0443 C Y/S. The post trial briefs submitted by all parties in this litigation are being supplied to the Office with this Information Disclosure Statement. As of October 19, 2004 the court had not rendered an opinion.

Since this Statement is being filed after the period specified in §1.97(b), but

before the mailing date of a final action or a notice of allowance, please charge the amount of \$180.00, the fee under 37 C.F.R. 1.17(p), and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840.

Applicants request consideration of this information.


Respectfully submitted,



Nelsen L. Lentz
Attorney for Applicants
Registration No. 38,537
Phone: 317-276-1207

Eli Lilly and Company
Patent Division/NLL
P.O. Box 6288
Indianapolis, Indiana 46206-6288

October 20, 2004



Sheet 1 of 2

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. G-12651	Serial No 10/023,132
	Applicants Jiban Kumar Chakrabarti et al.	
	Filing Date December 18, 2001	Group 1624

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US 4,115,574	09-19-1978	Chakrabarti et al.	
	AB	US 5,051,516	09-24-1991	Chakrabarti et al.	
	AC	US 5,605,897	2-25-1997	Beasley, Jr. et al.	
	AD	US 5,627,178	05-06-1997	Chakrabarti et al.	
	AE	US 5,817,655	10-06-1998	Chakrabarti et al.	
	AF	US 5,817,656	10-06-1998	Beasley, Jr. et al.	
	AG	US 5,817,657	10-06-1998	Beasley, Jr. et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
	BA					
	BB					
	BC					
	BD					
	BE					
	BF					
	BG					
	BH					
	BI					



FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. G-12651	Serial No 10/023,132
	Applicants Jiban Kumar Chakrabarti et al.	
	Filing Date December 18, 2001	Group 1624

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CA	C.A. ALTAR, ET AL., Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists, Naunyn-Schmiedeberg's Arch. Pharmacol, 1988, 162-168, 338	
	CB	H. R. SULLIVAN, ET AL., <i>In Vitro</i> Thiomethylation - Studies with Flumazenil, Drug Metabolism and Disposition, 1985, 276-278, Vol. 13, No. 3	
	CC	H. G. SCHAUZU ET AL., A Free-Wilson Study of 4-Piperazinyl-10H-thienobenzodiazepine Analogues, Pharmazie, 1983, H 8, 38	
	CD	JIBAN K. CHAKRABARTI ET AL., 4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as Potential Neuroleptics, J. Med. Chem., 1980, 878-884, 23	
	CE	JIBAN K. CHAKRABARTI ET AL., 10-Piperazinyl-4H-thieno[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as Potential Neuroleptics, J. Med. Chem., 1980, 884-889, 23	
	CF	JIBAN K. CHAKRABARTI ET AL., Effects of Conformationally Restricted 4-Piperazinyl-10H-thienobenzodiazepine Neuroleptics on Central Dopaminergic and Cholinergic Systems, J. Med. Chem., 1982, 1133-1140, 25	
	CG	JIBAN K. CHAKRABARTI ET AL., Synthesis and Pharmacological Evaluation of CNS Activities of [1,2,3]Triazolo[4,5-b][1,5]-, Imidazolo[4,5-b][1,5]-, and Pyrido[2,3-b][1,5]benzodiazepines. 10-Piperazinyl-4H-1,2,3-Triazolo[4,5-b][1,5]benzodiazepines with Neuroleptic Activity, J. Med. Chem, 1989, 2375-2381, 32	
	CH	JIBAN K. CHAKRABARTI ET AL., Synthesis and Pharmacological Evaluation of a Series of 4-Piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as Potential Anxiolytics, J. Med. Chem., 1989, 2573-2582, 32	
	CI	Lilly's Post-Trial Brief	
	CJ	Lilly's Motion for Leave to File Attached Supplemental Post-Trial Brief	
	CK	Defendant Dr. Reddy's Laboratories, Ltd.'s Notice of Filing Corrected Post-Trial Brief, Findings of Fact and Conclusions of Law	
	CL	Dr. Reddy's Laboratories, Ltd.'s Corrected Post-Trial Brief	
	CM	Zenith's Post-Trial Brief	
	CN	Zenith's Post-Trial Reply Brief	
Examiner Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.